FLUTICASONE FUROATE - Generic Drug Details

What are the generic sources for fluticasone furoate and what is the scope of freedom to operate?

Fluticasone furoate is the generic ingredient in four branded drugs marketed by Glaxosmithkline, Haleon Us Holdings, and Glaxo Grp Ltd, and is included in four NDAs. There are eleven patents protecting this compound. Additional information is available in the individual branded drug profile pages.

Four suppliers are listed for this compound.

Summary for FLUTICASONE FUROATE

International Patents:	120
US Patents:	11
Tradenames:	4
Applicants:	3
NDAs:	4
Drug Master File Entries:	5
Finished Product Suppliers / Packagers:	4
Raw Ingredient (Bulk) Api Vendors:	41
Clinical Trials:	162
Drug Prices:	Drug price trends for FLUTICASONE FUROATE
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for FLUTICASONE FUROATE
What excipients (inactive ingredients) are in FLUTICASONE FUROATE?	FLUTICASONE FUROATE excipients list
DailyMed Link:	FLUTICASONE FUROATE at DailyMed

See drug prices for FLUTICASONE FUROATE

DrugPatentWatch^® Estimated Loss of Exclusivity (LOE) Date for FLUTICASONE FUROATE

Dosage:

SPRAY, METERED;NASAL

^*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.

Recent Clinical Trials for FLUTICASONE FUROATE

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
Western University, Canada	PHASE4
University of Alabama at Birmingham	PHASE2
Thammasat University	PHASE4

See all FLUTICASONE FUROATE clinical trials

Pharmacology for FLUTICASONE FUROATE

Drug Class	Corticosteroid
Mechanism of Action	Corticosteroid Hormone Receptor Agonists

Anatomical Therapeutic Chemical (ATC) Classes for FLUTICASONE FUROATE

D07AC	Corticosteroids, potent (group III)
D07A	CORTICOSTEROIDS, PLAIN
D07	CORTICOSTEROIDS, DERMATOLOGICAL PREPARATIONS
D	Dermatologicals

R01AD	Corticosteroids
R01A	DECONGESTANTS AND OTHER NASAL PREPARATIONS FOR TOPICAL USE
R01	NASAL PREPARATIONS
R	Respiratory system

R01AD	Corticosteroids
R01A	DECONGESTANTS AND OTHER NASAL PREPARATIONS FOR TOPICAL USE
R01	NASAL PREPARATIONS
R	Respiratory system

R03BA	Glucocorticoids
R03B	OTHER DRUGS FOR OBSTRUCTIVE AIRWAY DISEASES, INHALANTS
R03	DRUGS FOR OBSTRUCTIVE AIRWAY DISEASES
R	Respiratory system

R03BA	Glucocorticoids
R03B	OTHER DRUGS FOR OBSTRUCTIVE AIRWAY DISEASES, INHALANTS
R03	DRUGS FOR OBSTRUCTIVE AIRWAY DISEASES
R	Respiratory system

Paragraph IV (Patent) Challenges for FLUTICASONE FUROATE

Tradename	Dosage	Ingredient	Strength	NDA	ANDAs Submitted	Submissiondate
FLONASE SENSIMIST ALLERGY RELIEF	Nasal Spray	fluticasone furoate	27.5 mcg	022051	1	2011-07-15

US Patents and Regulatory Information for FLUTICASONE FUROATE

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Glaxosmithkline	TRELEGY ELLIPTA	fluticasone furoate; umeclidinium bromide; vilanterol trifenatate	POWDER;INHALATION	209482-001	Sep 18, 2017		RX	Yes	Yes			Y	Y
Glaxo Grp Ltd	BREO ELLIPTA	fluticasone furoate; vilanterol trifenatate	POWDER;INHALATION	204275-002	Apr 30, 2015		RX	Yes	Yes					Y
Glaxo Grp Ltd	BREO ELLIPTA	fluticasone furoate; vilanterol trifenatate	POWDER;INHALATION	204275-002	Apr 30, 2015		RX	Yes	Yes					Y
Glaxosmithkline	TRELEGY ELLIPTA	fluticasone furoate; umeclidinium bromide; vilanterol trifenatate	POWDER;INHALATION	209482-001	Sep 18, 2017		RX	Yes	Yes			Y
Glaxo Grp Ltd	BREO ELLIPTA	fluticasone furoate; vilanterol trifenatate	POWDER;INHALATION	204275-003	May 12, 2023		RX	Yes	Yes					Y
Glaxosmithkline	TRELEGY ELLIPTA	fluticasone furoate; umeclidinium bromide; vilanterol trifenatate	POWDER;INHALATION	209482-002	Sep 9, 2020		RX	Yes	Yes			Y

Expired US Patents for FLUTICASONE FUROATE

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Haleon Us Holdings	FLONASE SENSIMIST ALLERGY RELIEF	fluticasone furoate	SPRAY, METERED;NASAL	022051-002	Aug 2, 2016
Glaxosmithkline	ARNUITY ELLIPTA	fluticasone furoate	POWDER;INHALATION	205625-003	May 17, 2018
Glaxosmithkline	ARNUITY ELLIPTA	fluticasone furoate	POWDER;INHALATION	205625-002	Aug 20, 2014
Haleon Us Holdings	FLONASE SENSIMIST ALLERGY RELIEF	fluticasone furoate	SPRAY, METERED;NASAL	022051-002	Aug 2, 2016
Glaxosmithkline	ARNUITY ELLIPTA	fluticasone furoate	POWDER;INHALATION	205625-002	Aug 20, 2014
Glaxosmithkline	ARNUITY ELLIPTA	fluticasone furoate	POWDER;INHALATION	205625-001	Aug 20, 2014

EU/EMA Drug Approvals for FLUTICASONE FUROATE

Company	Drugname	Inn	Product Number / Indication	Status	Generic	Biosimilar	Orphan	Marketing Authorisation	Marketing Refusal
GlaxoSmithKline (Ireland) Limited	Avamys	fluticasone furoate	EMEA/H/C/000770Adults, adolescents (12 years and over) and children (6-11 years). Avamys is indicated for the treatment of the symptoms of allergic rhinitis.	Authorised	no	no	no	2008-01-11
Glaxo Group Ltd.	Alisade	fluticasone furoate	EMEA/H/C/001019Adults, adolescents (12 years and over) and children (6 - 11 years). Alisade is indicated for the treatment of the symptoms of allergic rhinitis.	Withdrawn	no	no	no	2008-10-06

International Patents for FLUTICASONE FUROATE

Country	Patent Number	Title	Estimated Expiration
Austria	E476260
Australia	2006235671	A fluid dispensing device
Brazil	PI0610671	dispositivo de dispensação de fluido para dispensar produto fluido, e, uso do dispensador
Canada	2603740	DISPOSITIF DE DISTRIBUTION DE FLUIDE (A FLUID DISPENSING DEVICE)
China	101528357	A fluid dispensing device
Cyprus	1111247

Supplementary Protection Certificates for FLUTICASONE FUROATE

Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
2506844	SPC/GB18/020	United Kingdom		PRODUCT NAME: A PHARMACEUTICAL COMBINATION PRODUCT COMPRISING A PHARMACEUTICALLY ACCEPTABLE SALT OF UMECLIDINIUM (E.G. UMECLIDINIUM BROMIDE), VILANTEROL OR A PHARMACEUTICALLY ACCETPABLE SALT THEREOF (E.G. VILANTEROL TRIFENATATE), AND FLUTICASONE FUROATE; REGISTERED: UK EU/1/17/1236/001(NI) 20171117; UK EU/1/17/1236/002(NI) 20171117; UK EU/1/17/1236/003(NI) 20171117; UK PLGB 19494/0287 20171117
2506844	132018000000341	Italy		PRODUCT NAME: UN PRODOTTO DI COMBINAZIONE FARMACEUTICA COMPRENDENTE UN SALE FARMACEUTICAMENTE ACCETTABILE DI UMECLIDINIO (AD ESEMPIO BROMURO DI UMECLIDINIO), VILANTEROLO O UN SUO SALE FARMACEUTICAMENTE ACCETTABILE (AD ESEMPIO VILANTEROLO TRIFENATATO) E UN FUROATO(TRELEGY ELLIPTA - FLUTICASONE FUROATO/UMECLIDINIO/VILANTEROLO); AUTHORISATION NUMBER(S) AND DATE(S): EU/1/17/1236, 20171117
1305329	SPC/GB08/026	United Kingdom		PRODUCT NAME: FLUTICASONE FUROATE AND SOLVATES THEREOF; REGISTERED: UK EU/1/07/434/001 20080116; UK EU/1/07/434/002 20080116; UK EU/1/07/434/003 20080116
1519731	13C0067	France		PRODUCT NAME: AZELASTINE OU SES SELS PHARMACEUTIQUEMENT ACCEPTABLES ET UN ESTER PHARMACEUTIQUEMENT ACCEPTABLE DE FLUTICASONE; NAT. REGISTRATION NO/DATE: NL41755 20130925; FIRST REGISTRATION: SK - 24/0055/13-S 20130215
1519731	92269	Luxembourg		PRODUCT NAME: AZELASTINE,OU UN SEL PHARMACEUTIQUEMENT ACCEPTABLE DE CELUICI,ET UN ESTER PHARMACEUTIQUEMENT ACCEPTABLE DE FLUTICASONE
2506844	1890025-8	Sweden		PRODUCT NAME: COMBINATION OF A PHARMACEUTICALLY ACCEPTABLE SALT OF UMECLIDINIUM (E.G. UMECLIDINIUM BROMIDE), VILANTEROL OR A PHARMACEUTICALLY ACCEPTABLE SALT THEROF (E.G. VILANTEROL TRIFENATATE) AND FLUTICASONE FUROATE.; REG. NO/DATE: EU/1/17/1236 20171117

Fluticasone Furoate Market Dynamics, Patent Exclusivity, and Financial Trajectory

Last updated: September 15, 2026

Fluticasone furoate is a long-acting inhaled corticosteroid whose commercial value is concentrated in GSK's combination products: Trelegy Ellipta, Breo Ellipta, Relvar Ellipta, and Arnuity Ellipta. The molecule also underpins the over-the-counter nasal product Flonase Sensimist. Its financial trajectory is therefore tied less to standalone ingredient sales than to respiratory combination therapy, Ellipta device adoption, COPD and asthma prevalence, and the timing of generic or authorized-generic competition.

The highest-value product is Trelegy Ellipta, which combines fluticasone furoate, umeclidinium, and vilanterol. Trelegy has become a major growth product for GSK as the company shifts respiratory revenue toward once-daily triple therapy. Breo Ellipta and Relvar Ellipta remain material but face greater maturity risk. Fluticasone furoate's patent estate is product-specific, with protection distributed across active-ingredient, combination, formulation, inhaler-device, manufacturing, and method-of-use claims.

What is fluticasone furoate and how is it marketed?

Fluticasone furoate is a synthetic corticosteroid with potent anti-inflammatory activity. It is administered through inhaled and intranasal products.

Product	Active ingredients	Main indication	Manufacturer or commercial owner	U.S. status
Arnuity Ellipta	Fluticasone furoate	Maintenance treatment of asthma	GSK	Prescription
Breo Ellipta	Fluticasone furoate and vilanterol	Asthma and COPD maintenance therapy	GSK	Prescription
Relvar Ellipta	Fluticasone furoate and vilanterol	Asthma and COPD maintenance therapy	GSK	Ex-U.S. brand
Trelegy Ellipta	Fluticasone furoate, umeclidinium, and vilanterol	COPD and asthma maintenance therapy	GSK	Prescription
Flonase Sensimist	Fluticasone furoate	Allergic rhinitis	Haleon, formerly within GSK consumer-health operations	OTC

The molecule is not generally commercialized as a high-value standalone inhaled corticosteroid. Revenue comes from branded combinations and the OTC nasal formulation.

How large is the fluticasone furoate market?

No public financial statement reports global fluticasone furoate revenue as a separate line item. GSK reports sales by product and respiratory franchise, not by active pharmaceutical ingredient. The best commercial proxy is the combined performance of Trelegy, Breo/Relvar, and Arnuity, supplemented by OTC Flonase Sensimist sales where disclosed.

GSK's annual reports show the following market pattern:

Commercial asset	Financial trajectory	Main market driver
Trelegy Ellipta	Strong growth	Expansion of single-inhaler triple therapy in COPD and asthma
Breo/Relvar Ellipta	Mature to declining or mixed	Established maintenance market and pricing pressure
Arnuity Ellipta	Smaller, mature product	Asthma maintenance and formulary access
Flonase Sensimist	Consumer-health product with seasonal demand	Allergic rhinitis and OTC brand recognition

Trelegy has become the principal economic engine for fluticasone furoate-containing respiratory products. GSK reported Trelegy sales of approximately £2.7 billion in 2023, compared with roughly £1.3 billion for the Breo/Relvar franchise, according to the company's 2023 annual report. The exact contribution attributable to fluticasone furoate cannot be isolated because the products contain multiple active ingredients and the reports do not allocate revenue by molecule (GSK, 2024).

Why Trelegy is the key financial asset

Trelegy benefits from three commercial characteristics:

1. It combines inhaled corticosteroid, long-acting muscarinic antagonist, and long-acting beta agonist therapy in one once-daily inhaler.
2. It targets COPD, a large chronic market with substantial treatment persistence.
3. It has expanded into asthma, widening the eligible patient population.

The product competes with other single-inhaler triple therapies, including AstraZeneca's Breztri Aerosphere, which contains budesonide, glycopyrrolate, and formoterol. Trelegy and Breztri differ in corticosteroid, bronchodilator combination, device, dosing frequency, and market access.

When does fluticasone furoate lose exclusivity?

Fluticasone furoate does not have one universal loss-of-exclusivity date. Exclusivity depends on the specific product, dosage strength, delivery device, approved indication, patent listing, and jurisdiction.

The relevant U.S. products entered the market at different times:

Product	Key U.S. FDA milestone	Exclusivity profile
Breo Ellipta	FDA approval in 2013	Combination and device patents are more relevant than the original active-ingredient exclusivity
Arnuity Ellipta	FDA approval in 2014	Asthma maintenance product with product-specific patent protection
Trelegy Ellipta	FDA approval in 2017	Later product launch with separate combination, device, and method-of-use protections
Flonase Sensimist	FDA approval as an OTC product in 2016	OTC monograph/approved-product framework differs from prescription inhalers

For branded inhalers, generic entry usually depends on the full legal and technical package rather than the date of the five-year new chemical entity period. Inhaled products can be difficult to copy because an applicant must address the active ingredients, formulation, device, dose delivery, manufacturing controls, and FDA substitutability requirements.

What patents protect fluticasone furoate products?

Protection is distributed across several patent categories:

Active-ingredient and chemical patents

The original fluticasone furoate chemical patent families protect the molecule and related corticosteroid chemistry. Those rights are generally older than the product-specific Ellipta combination and device patents and are less likely to determine current U.S. market exclusivity.

Combination patents

Breo/Relvar patents cover combinations of fluticasone furoate with vilanterol. Trelegy-related patents cover the three-drug combination of fluticasone furoate, umeclidinium, and vilanterol, including specific ratios and dose strengths.

Formulation patents

Formulation protection can cover:

• Dry-powder blends
• Carrier particles, such as lactose-based systems
• Particle-size distribution
• Dose uniformity
• Stability characteristics
• Specific strengths and dose ratios

These claims can create technical barriers even after broad chemical claims expire.

Inhaler-device patents

The Ellipta inhaler is central to the commercial product. Device patents may cover the inhaler housing, blister arrangement, dose indexing, airflow pathway, powder release, and actuation mechanism. A competing product may avoid literal infringement by using a different device, but that can increase development, clinical, and regulatory costs.

Method-of-use patents

Method patents cover maintenance treatment of asthma or COPD, including once-daily administration and use in specified patient populations. Method-of-use claims can support litigation against an ANDA applicant that seeks approval for a patented indication, although carve-outs and label changes can reduce the scope of infringement.

The FDA Orange Book is the controlling public source for patents listed against approved U.S. prescription products. Listings should be reviewed separately for Breo Ellipta, Arnuity Ellipta, and Trelegy Ellipta because the patents and expiration dates are not interchangeable (FDA, 2024).

What is the Orange Book status of fluticasone furoate products?

The Orange Book framework applies to approved prescription products, not to fluticasone furoate as an abstract molecule. Each NDA may contain different listed patents.

Product	Orange Book relevance	Principal legal issues
Breo Ellipta	Listed patents may cover the combination, formulation, inhaler, and methods of use	ANDA certification, device design, combination claims
Arnuity Ellipta	Product-specific listings for inhaled corticosteroid therapy	Formulation, dose strength, asthma-use claims
Trelegy Ellipta	Later-generation combination and device protection	Triple-combination claims, device patents, COPD and asthma methods
Flonase Sensimist	OTC product; not analyzed like a standard prescription NDA	OTC regulatory pathway and brand competition

Patent expiry should not be assessed from one Orange Book date. A later-expiring device or method patent can remain commercially relevant after an earlier composition patent expires.

Are there Paragraph IV challenges to fluticasone furoate products?

Paragraph IV litigation risk exists for prescription products when an ANDA applicant certifies that an Orange Book-listed patent is invalid, unenforceable, or not infringed. The applicant must typically provide a notice letter to the NDA holder, which can trigger a patent-infringement action and a statutory stay of FDA approval for up to 30 months, subject to statutory exceptions.

For fluticasone furoate products, the litigation analysis is complicated by the absence of a conventional tablet-style generic pathway. An ANDA applicant must demonstrate pharmaceutical equivalence and, for an orally inhaled product, therapeutic equivalence under FDA requirements. Device differences can affect substitutability.

Potential Paragraph IV targets include:

• Breo Ellipta generic equivalents
• Arnuity Ellipta generic equivalents
• Trelegy Ellipta generic equivalents
• Combination products using alternative inhaler devices

Public litigation searches should cover the Hatch-Waxman docket, the U.S. District Court for the District of Delaware, the District of New Jersey, and other districts where inhaler patent cases are filed. Orange Book listings and FDA-approved product databases remain the primary sources for active patent and approval status.

What generic entry risks exist for fluticasone furoate?

Generic entry risk is highest where the branded product has:

• A large addressable population
• High annual sales
• Expiring composition or formulation claims
• A technically replicable device
• An established FDA product-specific guidance pathway
• A manageable clinical equivalence burden

The risk is lower where protection depends on a complex combination-device system or where the applicant must resolve multiple patents.

Breo Ellipta and Arnuity Ellipta

These products are more exposed to mature-product competition because they launched earlier than Trelegy. Generic entry could reduce net pricing, increase rebate demands, and shift formulary volume. The impact would depend on whether a generic is automatically substitutable or requires physician-directed switching.

Trelegy Ellipta

Trelegy has higher revenue exposure but also a more complex product architecture. A generic applicant must address three active ingredients, dose delivery, device performance, and multiple indications. That complexity can delay entry, but it does not eliminate the risk.

A first generic or authorized generic could materially affect GSK's respiratory growth outlook because Trelegy has become a major contributor to the company's sales expansion.

Is there biosimilar risk for fluticasone furoate?

There is no biosimilar pathway for fluticasone furoate. Biosimilars apply to biological products. Fluticasone furoate is a chemically synthesized small molecule.

The relevant competitors are:

• ANDA-approved generics
• Authorized generics
• 505(b)(2) products
• Alternative inhaler combinations
• Therapeutically similar branded products
• OTC nasal corticosteroids

The absence of biosimilar risk does not mean the product is insulated from competition. Inhaled products can face complex generic substitution and therapeutic switching.

Which companies compete with fluticasone furoate products?

COPD

Trelegy competes primarily with:

• AstraZeneca's Breztri Aerosphere
• Boehringer Ingelheim's Stiolto Respimat, a dual bronchodilator
• Other LABA/LAMA combinations
• Separate-inhaler triple therapy

Asthma

Trelegy and Breo compete with:

• AstraZeneca's Symbicort and Breztri in relevant treatment segments
• Sanofi and Regeneron biologics for severe asthma
• Teva's AirDuo and related inhaled corticosteroid/LABA products
• Generic fluticasone propionate/salmeterol products
• Budesonide/formoterol products

Allergic rhinitis

Flonase Sensimist competes with:

• Flonase fluticasone propionate
• Nasacort triamcinolone
• Rhinocort budesonide
• Store-brand intranasal corticosteroids
• Antihistamine sprays and oral antihistamines

The most direct commercial threat differs by indication. Trelegy faces branded respiratory competition, while Flonase Sensimist faces strong OTC private-label and price competition.

How do fluticasone furoate products compare with competing drugs?

Attribute	Trelegy Ellipta	Breztri Aerosphere	Breo Ellipta	Symbicort
Corticosteroid	Fluticasone furoate	Budesonide	Fluticasone furoate	Budesonide
Long-acting beta agonist	Vilanterol	Formoterol	Vilanterol	Formoterol
Muscarinic antagonist	Umeclidinium	Glycopyrrolate	None	None
Therapy	Triple	Triple	Dual	Dual
Typical dosing	Once daily	Twice daily	Once daily	Twice daily
Device	Ellipta dry-powder inhaler	Aerosol metered-dose inhaler	Ellipta dry-powder inhaler	Aerosol inhaler
Main commercial role	COPD and asthma triple therapy	COPD and asthma triple therapy	COPD and asthma dual therapy	Asthma and COPD dual therapy

Trelegy's once-daily dosing and single-device triple therapy are central commercial differentiators. Breztri's aerosol device and twice-daily dosing create a different prescribing and adherence profile.

What licensing deals affect fluticasone furoate?

The major commercial arrangement is the GSK and Innoviva collaboration involving long-acting respiratory medicines, including vilanterol-containing products. Innoviva has retained economic interests in certain respiratory assets while GSK has handled commercialization for products such as Breo/Relvar and Trelegy-related therapies under the applicable agreements.

Fluticasone furoate's commercial economics therefore involve more than GSK product sales. Royalty obligations, collaboration payments, regional rights, and supply arrangements can affect net profitability. The precise terms differ by product and agreement and are reported in company filings rather than consolidated under a fluticasone furoate royalty line.

What is the FDA regulatory status?

FDA-approved prescription products containing fluticasone furoate include Arnuity Ellipta, Breo Ellipta, and Trelegy Ellipta. Flonase Sensimist is an OTC nasal product.

Regulatory risks include:

• New generic inhaler approvals
• Label expansion into asthma or COPD
• Device changes
• Manufacturing-site changes
• Product-specific equivalence requirements
• Postmarketing safety obligations
• Regulatory scrutiny of inhaled-powder dose consistency

GSK's financial trajectory depends on maintaining approval, supply reliability, formulary access, and label breadth across both COPD and asthma.

How strong is the fluticasone furoate patent estate?

The estate is strongest when assessed as a layered product portfolio rather than as a single molecule patent.

Protection layer	Strategic value
Original chemical patents	Historical foundation; generally less important for later product launches
Combination claims	High value for Breo and Trelegy
Formulation claims	Can delay technically equivalent products
Ellipta device claims	Important barrier to substitutable dry-powder products
Method-of-use claims	Supports indication-specific enforcement
Manufacturing claims	Can raise process-development and scale-up costs

The estate's commercial strength is greatest for Trelegy because the product combines multiple active ingredients with a proprietary device and broad chronic-disease indications. The principal weakness is that competing companies can develop different devices or alternative triple combinations that avoid direct copying.

What is the financial outlook for fluticasone furoate?

The near-term outlook is positive for Trelegy and mixed for older products.

Growth factors

• Continued COPD diagnosis and treatment
• Asthma label expansion
• Movement toward single-inhaler triple therapy
• Once-daily dosing
• Higher value per treated patient for triple therapy
• Expansion in international markets
• Persistent use in chronic maintenance treatment

Downside factors

• Generic or authorized-generic entry
• Rebates and payer negotiations
• Price controls and reference pricing outside the U.S.
• Competition from Breztri and other triple therapies
• Device switching costs
• Declining contribution from mature Breo/Relvar and Arnuity
• OTC pricing pressure for Flonase Sensimist

Revenue exposure is concentrated in Trelegy. A delayed generic launch would extend GSK's high-margin respiratory cash flow. A successful generic or competitive triple-therapy launch could reduce price and volume growth across the portfolio.

Key Takeaways

• Fluticasone furoate is commercially important because it powers GSK's Trelegy, Breo, Relvar, and Arnuity products.
• Trelegy Ellipta is the principal growth and revenue asset.
• Fluticasone furoate revenue is not disclosed separately from combination-product sales.
• Patent protection is product-specific and includes combinations, formulations, Ellipta devices, methods of use, and manufacturing.
• Generic competition, not biosimilar competition, is the relevant erosion risk.
• Breo and Arnuity face earlier maturity risk than Trelegy.
• Trelegy's triple-drug and device architecture creates a higher entry barrier but also a larger financial exposure if generic substitution occurs.
• Flonase Sensimist has a separate OTC competitive profile dominated by private-label and intranasal corticosteroid alternatives.
• The Orange Book must be reviewed by NDA because there is no single fluticasone furoate expiration date.

FAQs

Is fluticasone furoate the same as fluticasone propionate?

No. Both are inhaled or intranasal corticosteroids, but they are different chemical entities with different potency, pharmacokinetics, formulations, products, and patent histories.

Which GSK drug contains fluticasone furoate and umeclidinium?

Trelegy Ellipta contains fluticasone furoate, umeclidinium, and vilanterol. Umeclidinium is not present in Breo Ellipta or Arnuity Ellipta.

Can fluticasone furoate be used as a rescue inhaler?

No. Fluticasone furoate is a maintenance corticosteroid. It is not intended to provide rapid relief of acute bronchospasm.

Does Flonase Sensimist have the same patent risks as Trelegy Ellipta?

No. Flonase Sensimist is an OTC nasal product with a different regulatory and commercial framework. Trelegy is a prescription inhaled combination product with Orange Book-listed patent issues and ANDA-related risks.

What product has the greatest financial exposure to fluticasone furoate patent expiry?

Trelegy Ellipta has the greatest exposure because it is the largest and fastest-growing commercial product containing fluticasone furoate. Its risk is determined by the combined expiry and enforceability of product, device, formulation, and method patents.

References

1. AstraZeneca. (2024). Annual report and form 20-F 2023. AstraZeneca PLC.

2. GlaxoSmithKline plc. (2024). Annual report 2023. GSK plc.

3. U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations: Orange Book. U.S. Department of Health and Human Services.

4. U.S. Food and Drug Administration. (2024). Drugs@FDA: FDA-approved drugs database. U.S. Department of Health and Human Services.

5. U.S. Food and Drug Administration. (2023). Product-specific guidances for generic drug development. U.S. Department of Health and Human Services.

6. Innoviva, Inc. (2024). Annual report on Form 10-K for fiscal year 2023. Innoviva, Inc.